<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41036">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572167</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-025</org_study_id>
    <nct_id>NCT02572167</nct_id>
  </id_info>
  <brief_title>A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety profile and antitumor activity of
      brentuximab vedotin administered in combination with nivolumab in patients with relapsed or
      refractory Hodgkin lymphoma (HL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the safety profile and antitumor activity when brentuximab vedotin
      is combined with nivolumab. Patients will be treated for up to four 21-day cycles with
      brentuximab vedotin 1.8 mg/kg and nivolumab 3 mg/kg.

      There will be 2 parts to this study. In Part 1, the safety of combination treatment will be
      evaluated by a Safety Monitoring Committee (SMC) prior to expansion of enrollment to
      evaluate treatment effect in Part 2. Part 2 of the study will further characterize safety
      and evaluate the antitumor activity of brentuximab vedotin combined with nivolumab by
      enrolling patients at the recommended dose schedule determined in Part 1.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 7 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival post-autologous stem cell transplant</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Brentuximab Vedotin + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brentuximab vedotin plus nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles</description>
    <arm_group_label>Brentuximab Vedotin + Nivolumab</arm_group_label>
    <other_name>SGN-35, ADCETRIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>3 mg/kg by intravenous (IV) infusion for up to 4 cycles</description>
    <arm_group_label>Brentuximab Vedotin + Nivolumab</arm_group_label>
    <other_name>BMS-936558, OPDIVO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsed or refractory Hodgkin lymphoma following failure of standard frontline
             chemotherapy for the treatment of classical Hodgkin lymphoma

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Previously treated with brentuximab vedotin, immune-oncology agents, or received an
             allogeneic or autologous stem cell transplant

          -  Documented history of a cerebral vascular event

          -  History of another invasive malignancy that has not been in remission for at least 3
             years

          -  History of progressive multifocal leukoencephalopathy (PML)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Campbell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaemee Bautista</last_name>
      <phone>626-218-3033</phone>
      <email>jbautista@coh.org</email>
    </contact>
    <investigator>
      <last_name>Alex Herrera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tessa Hapanowicz</last_name>
      <phone>650-721-4096</phone>
      <email>tkhap@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sipra Choudhury</last_name>
      <phone>650-736-2563</phone>
      <email>schoudhury@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ranjana Advani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Newcomb</last_name>
      <phone>617-632-2328</phone>
      <email>AshleyN_Newcomb@DFCI.Harvard.Edu</email>
    </contact>
    <contact_backup>
      <last_name>Sara Schlegel</last_name>
      <phone>617-632-6840</phone>
      <email>sschlegel@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ann LaCasce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Houde</last_name>
      <phone>313-576-9381</phone>
      <email>houdec@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Radhakrishnan Ramchandren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayo Clinic Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Stephen Ansell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Fischer</last_name>
      <phone>314-362-3021</phone>
      <email>afischer@dom.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Kloeppinger</last_name>
      <phone>314-362-4206</phone>
      <email>lkloeppi@dom.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nancy Bartlett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Vose</last_name>
      <phone>402-559-5166</phone>
      <email>jmvose@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maribeth Hohenstein</last_name>
      <phone>402-559-9053</phone>
      <email>mahohens@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Vose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Yannotti</last_name>
      <phone>551-996-5168</phone>
      <email>Kara.Yannotti@HackensackMeridian.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center - Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz</last_name>
      <phone>212-639-2696</phone>
      <email>moskowia@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Alison Moskowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Moskowitz</last_name>
      <phone>212-639-2696</phone>
      <email>moskowia@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Alison Moskowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Shearin</last_name>
      <phone>919-668-2556</phone>
      <email>sherra.shearin@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stacy Murray</last_name>
      <phone>919-668-1211</phone>
      <email>stacy.murray@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anne Beaven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Cancer Hospital / Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Christian</last_name>
      <phone>614-293-2268</phone>
      <email>Beth.Christian@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Beth Christian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles A. Sammons Cancer Center / Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Townsend</last_name>
      <phone>214-818-8382</phone>
      <email>grace.townsend@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Houston Holmes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>October 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monomethyl auristatin E</keyword>
  <keyword>Antigens, CD30</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>Antibodies, Monoclonal</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Autologous stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
